Diabetes Mellitus

Metabolic Diseases
91
Pipeline Programs
30
Companies
50
Clinical Trials
18
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
15
2
10
2
31
31
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1071%
Peptide
321%
Monoclonal Antibody
17%
+ 103 programs with unclassified modality

On Market (18)

Approved therapies currently available

Takeda
ACTOSApproved
pioglitazone
Takeda
oral1999
AstraZeneca
BYETTAApproved
exenatide
AstraZeneca
GLP-1 Receptor Agonist [EPC]subcutaneous2005
U
EXENATIDE SYNTHETICApproved
exenatide
Unknown Company
GLP-1 Receptor Agonist [EPC]subcutaneous2024
M&
JANUVIAApproved
sitagliptin
Merck & Co.
oral2006
Sanofi
LANTUSApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Sanofi
LANTUS SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]injection2000
Novo Nordisk
LEVEMIRApproved
insulin detemir
Novo Nordisk
injection2005
Novo Nordisk
LEVEMIR FLEXPENApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR FLEXTOUCHApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR INNOLETApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR PENFILLApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
U
METFORMIN HYDROCHLORIDEApproved
metformin
Unknown Company
oral2018
Takeda
NESINAApproved
alogliptin
Takeda
oral2013
U
PIOGLITAZONE HYDROCHLORIDEApproved
pioglitazone
Unknown Company
oral2013
Bayer
PRECOSEApproved
acarbose
Bayer
oral1995
Sanofi
TOUJEO MAX SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
Sanofi
TOUJEO SOLOSTARApproved
insulin glargine
Sanofi
Insulin Analog [EPC]subcutaneous2015
U
ZITUVIOApproved
sitagliptin
Unknown Company
Dipeptidyl Peptidase 4 Inhibitor [EPC]oral2023

Competitive Landscape

35 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
19 programs
3
14
1
Pioglitazone and metforminPhase 41 trial
AlogliptinPhase 3Small Molecule1 trial
AlogliptinPhase 3Small Molecule1 trial
NESINA(Alogliptin)Phase 3Small Molecule1 trial
Alogliptin and metforminPhase 31 trial
+14 more programs
Active Trials
NCT00755846Completed265Est. Oct 2005
NCT00762736Completed704Est. Oct 2005
NCT00763347Terminated82Est. Feb 2007
+16 more trials
Pfizer
PfizerNEW YORK, NY
11 programs
2
3
4
1
Piperacillin/TazobactamPhase 41 trial
Inhaled Human InsulinPhase 31 trial
Inhaled InsulinPhase 31 trial
Inhaled InsulinPhase 31 trial
Subcutaneous InsulinPhase 31 trial
+6 more programs
Active Trials
NCT01678183Completed74Est. Jan 2015
NCT00448032CompletedEst. Mar 2007
NCT00447629CompletedEst. Mar 2007
+8 more trials
Novo Nordisk
10 programs
1
1
4
Basal-bolus detemir-aspart insulin regimenPhase 4
DetemirPhase 41 trial
Sterile air injectionPhase 41 trial
insulin detemirPhase 41 trial
IDegLiraPhase 31 trial
+5 more programs
Active Trials
NCT05314140Withdrawn0Est. Jan 2028
NCT00421850Completed3,491Est. Jan 2005
NCT01892319Completed2,446Est. Sep 2019
+5 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
7 programs
2
1
NPHPhase 41 trial
Human Insulin Inhalation PowderPhase 31 trial
PioglitazonePhase 31 trial
Epidemiological interventionN/A1 trial
ManagementN/A1 trial
+2 more programs
Active Trials
NCT01117831Completed600Est. Feb 2013
NCT00377117Completed39Est. Jul 2007
NCT00489242Completed72Est. Sep 2005
+4 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
1
1
1
ExenatidePhase 3Peptide1 trial
saxagliptinPhase 1Small Molecule1 trial
Indian Phenotype RegistryN/A1 trial
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy N/A1 trial
Active Trials
NCT03363594Completed40,000Est. Jun 2019
NCT02578563Completed201Est. Dec 2018
NCT01192139Completed30Est. Dec 2009
+1 more trials
M&
Merck & Co.RAHWAY, NJ
4 programs
3
1
MetforminPhase 31 trial
OmarigliptinPhase 3Small Molecule2 trials
SitagliptinPhase 3Small Molecule1 trial
Patient ActivationN/A1 trial
Active Trials
NCT01087073Completed6,209Est. Nov 2016
NCT02484209Withdrawn0Est. Nov 2016
NCT01814748Completed203Est. Sep 2015
+2 more trials
Bayer
BayerLEVERKUSEN, Germany
3 programs
1
1
Novel strategy AspirinPhase 41 trial
AcarbosePhase 31 trial
Bay G5421 GlucobayN/A1 trial
Active Trials
NCT01961388Withdrawn0Est. Jun 2017
NCT01010100Completed204Est. May 2007
NCT02520921Completed2,484Est. Jul 2024
Sanofi
SanofiPARIS, France
3 programs
1
1
insulin glarginePhase 41 trial
LixisenatidePhase 1/2Peptide1 trial
Risk Factors for Diabetes After Stem Cell TransplantationN/A1 trial
Active Trials
NCT00539851Completed87Est. Mar 2010
NCT02308254Unknown30Est. Apr 2016
NCT00322075Completed35Est. Nov 2006
Design Therapeutics
2 programs
1
Subcutaneous glargine insulinPhase 41 trial
Verio Pattern Alert® activatedN/A1 trial
Active Trials
NCT02521506CompletedEst. Dec 2016
NCT02706119CompletedEst. Apr 2018
Astellas
AstellasChina - Shenyang
2 programs
1
1
PregabalinPhase 41 trial
FK614Phase 21 trial
Active Trials
NCT00036192Completed200Est. Mar 2006
NCT01713426Completed568Est. Sep 2013
ADvantage Therapeutics
1 program
1
Pharmacist ManagementPhase 41 trial
Active Trials
NCT00869076CompletedEst. Dec 2007
DS
Daiichi SankyoChina - Shanghai
1 program
1
PravastatinPhase 4Small Molecule1 trial
Active Trials
NCT02754739Completed44Est. Aug 2017
Roche
3 programs
1
1
Generex Oral-lyn™Phase 31 trial
Telmisartan, BisoprololPhase 2/3Small Molecule1 trial
Eversense XL CGM SystemN/A1 trial
Active Trials
NCT03445065Completed239Est. Aug 2020
NCT00562952Completed300Est. Dec 2011
NCT00668850Unknown500Est. Sep 2011
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
1,2 dithiolane 3 valeric acidPhase 31 trial
Active Trials
NCT01208948Completed520Est. Dec 2005
Alkermes
AlkermesDUBLIN 4, Ireland
1 program
1
Human Insulin Inhalation PowderPhase 3
Genentech
1 program
1
RanibizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00473382Completed382Est. Sep 2012
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
VEGF Trap-EyePhase 3
City Therapeutics
City TherapeuticsMA - Cambridge
3 programs
1
1
EGCGPhase 2/31 trial
Islet Transplantation + ImmunosuppressionPhase 11 trial
Mobile Insulin Titration InterventionN/A1 trial
Active Trials
NCT01879579CompletedEst. Jun 2015
NCT00706420Active Not RecruitingEst. Oct 2026
NCT02147041UnknownEst. Aug 2014
Oxurion
OxurionBelgium - Leuven
5 programs
2
3
Ranibizumab 0.5mgPhase 21 trial
THR-149 dose level 1Phase 21 trial
THR-687 dose level 1Phase 21 trial
THR-149 dose level 1Phase 11 trial
THR-687 dose level 1Phase 11 trial
Active Trials
NCT03511898CompletedEst. May 2019
NCT03666923CompletedEst. Nov 2019
NCT03499223CompletedEst. Jul 2019
+2 more trials
CRISPR Therapeutics
2 programs
1
1
VCTX211Phase 1/21 trial
VCTX210A unitPhase 11 trial
Active Trials
NCT05210530Completed7Est. Jan 2023
NCT05565248Recruiting40Est. Aug 2025
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
3 programs
1
Patient diabetic self-management using the diabetic patient portal toolsPhase 11 trial
Becaplermin nonusersN/A1 trial
Participation in LOFTS online tutorialN/A1 trial
Active Trials
NCT01235260CompletedEst. Mar 2011
NCT00470860Completed105Est. Aug 2005
NCT00221455Completed1,000Est. Sep 2007
J
JulpharUAE - Ras Al Khaimah
3 programs
3
Julphar Insulin NPhase 11 trial
Julphar Insulin RPhase 11 trial
human biphasic insulinPhase 11 trial
Active Trials
NCT02634528Completed85Est. Jan 2017
NCT02634515Completed26Est. Feb 2015
NCT02631928Completed73Est. Jun 2016
Akros Pharma
Akros PharmaNJ - Princeton
2 programs
2
JTT-251 or PlaceboPhase 11 trial
JTT-252 or PlaceboPhase 11 trial
Active Trials
NCT02106585Completed94Est. Aug 2014
NCT02120976Terminated85Est. Mar 2015
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 876Phase 12 trials
Active Trials
NCT01856881Terminated86Est. Mar 2015
NCT01492465Terminated47Est. Oct 2012
Abbott
AbbottABBOTT PARK, IL
10 programs
ADC blood glucose meterN/A1 trial
Abbott Sensor Based Glucose Monitoring SystemN/A4 trials
Comparison Study of Blood Glucose Monitoring Systems in People With DiabetesN/A1 trial
FreeStyle Libre 3N/A5 trials
FreeStyle Libre Flash Glucose Monitoring SystemN/A5 trials
+5 more programs
Active Trials
NCT01432275Completed179Est. Apr 2012
NCT03433573Completed103Est. May 2018
NCT02388815Completed89Est. Jul 2015
+18 more trials
Insulet
4 programs
Omnipod 5 Automated Glucose Control SystemN/A1 trial
Omnipod 5 SA2.0 SystemN/A1 trial
Omnipod M systemN/A1 trial
The Omnipod 5/Horizon HCL systemN/A1 trial
Active Trials
NCT06181721CompletedEst. Jan 2024
NCT06547918CompletedEst. Sep 2025
NCT07039981Active Not RecruitingEst. May 2026
+1 more trials
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
Clamp studyN/A1 trial
DSDN/A1 trial
Active Trials
NCT03358121Completed10Est. Oct 2017
NCT04183413Completed3,500Est. Dec 2023
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
BetacaroteneN/A1 trial
Active Trials
NCT01477112Completed117Est. Dec 2010
Beta Bionics
Beta BionicsIRVINE, CA
1 program
Bionic PancreasN/A1 trial
Active Trials
NCT04200313Completed440Est. Jan 2022
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
Closed-loop systemN/A1 trial
Active Trials
NCT02871089Active Not Recruiting96Est. Jul 2024

+5 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Design TherapeuticsSubcutaneous glargine insulin
BayerNovel strategy Aspirin
Eli Lilly and CompanyNPH
Daiichi SankyoPravastatin
AstellasPregabalin
Novo NordiskSterile air injection
Novo NordiskDetemir
Novo Nordiskinsulin detemir
ADvantage TherapeuticsPharmacist Management
Sanofiinsulin glargine
TakedaPioglitazone and metformin
PfizerPiperacillin/Tazobactam
Novo NordiskIDegLira
Merck & Co.Metformin
AstraZenecaExenatide

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 23,735 patients across 50 trials

NCT02706119Design TherapeuticsSubcutaneous glargine insulin

Insulin in Total Parenteral Nutrition

Start: Jul 2016Est. completion: Apr 2018
Phase 4Completed
NCT02520921BayerNovel strategy Aspirin

Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome

Start: Jun 2016Est. completion: Jul 20242,484 patients
Phase 4Completed
NCT01970241Eli Lilly and CompanyNPH

Inpatient Diabetes on Corticosteroids

Start: Jul 2014Est. completion: Jun 201685 patients
Phase 4Completed
NCT02754739Daiichi SankyoPravastatin

Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes

Start: Apr 2014Est. completion: Aug 201744 patients
Phase 4Completed
NCT01713426AstellasPregabalin

A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment

Start: Jul 2012Est. completion: Sep 2013568 patients
Phase 4Completed
NCT00894270Novo NordiskSterile air injection

Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees

Start: Nov 2008Est. completion: May 2009240 patients
Phase 4Completed
NCT00717288Novo NordiskDetemir

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir

Start: Jul 2008Est. completion: Jun 201082 patients
Phase 4Completed
NCT00607737Novo Nordiskinsulin detemir

Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes

Start: Jan 2008Est. completion: Jul 201040 patients
Phase 4Completed
NCT00869076ADvantage TherapeuticsPharmacist Management

Pharmacists Management of Diabetes

Start: May 2006Est. completion: Dec 2007
Phase 4Completed
NCT00322075Sanofiinsulin glargine

LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous

Start: Apr 2006Est. completion: Nov 200635 patients
Phase 4Completed
NCT00754403TakedaPioglitazone and metformin

Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes

Start: Jul 2005Est. completion: Oct 2006312 patients
Phase 4Completed
NCT00044746PfizerPiperacillin/Tazobactam

Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

Start: Oct 2000Est. completion: Jan 2003314 patients
Phase 4Completed
NCT03737240Novo NordiskIDegLira

IDegLira HIGH Trial

Start: Jan 2019Est. completion: Jul 2022145 patients
Phase 3Completed
NCT02484209Merck & Co.Metformin

DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)

Start: Feb 2016Est. completion: Nov 20160
Phase 3Withdrawn
NCT02229383AstraZenecaExenatide

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Start: Sep 2014Est. completion: Aug 2016464 patients
Phase 3Completed
NCT01890122TakedaAlogliptin

Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

Start: Sep 2013Est. completion: Oct 2015647 patients
Phase 3Completed
NCT01814748Merck & Co.Omarigliptin

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Start: May 2013Est. completion: Sep 2015203 patients
Phase 3Completed
NCT01751360TakedaSYR-472

SYR-472 Open-label Study

Start: Apr 2013Est. completion: Aug 201314 patients
Phase 3Completed
NCT01485614Merck & Co.Sitagliptin

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Start: Feb 2012Est. completion: Oct 2019200 patients
Phase 3Completed
NCT01521962TakedaAlogliptin

Study of Combination Therapy With SYR-322

Start: Feb 2012Est. completion: Mar 201367 patients
Phase 3Completed
NCT01433419TakedaTAK-875

Open-label Study of TAK-875

Start: Jan 2012Est. completion: Dec 2012333 patients
Phase 3Completed
NCT01433406TakedaTAK-875

Long-term Study of TAK-875

Start: Oct 2011Est. completion: Dec 20131,222 patients
Phase 3Completed
NCT01431807TakedaSYR-472

Long-term Study of SYR-472

Start: Sep 2011Est. completion: Jun 2013680 patients
Phase 3Completed
NCT00668850RocheGenerex Oral-lyn™

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

Start: Apr 2008Est. completion: Sep 2011500 patients
Phase 3Unknown
NCT00473382GenentechRanibizumab

A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

Start: Jun 2007Est. completion: Sep 2012382 patients
Phase 3Completed
NCT00286442TakedaAlogliptin and metformin

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

Start: Mar 2006Est. completion: Jun 2007527 patients
Phase 3Completed
NCT00306384TakedaAlogliptin

Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus

Start: Mar 2006Est. completion: Nov 20113,323 patients
Phase 3Completed
NCT00287066PfizerInhaled Human Insulin

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Start: Feb 2006Est. completion: Mar 200722 patients
Phase 3Terminated
NCT00286494TakedaAlogliptin and pioglitazone

Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus

Start: Feb 2006Est. completion: Aug 2007493 patients
Phase 3Completed
NCT00157339Eli Lilly and CompanyHuman Insulin Inhalation Powder

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

Start: Aug 2005Est. completion: May 2008299 patients
Phase 3Completed
NCT00134147PfizerInhaled Insulin

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

Start: Apr 2005Est. completion: May 20071,100 patients
Phase 3Completed
NCT00762957TakedaTAK-559

Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

Start: Nov 2004Est. completion: Dec 200415 patients
Phase 3Terminated
NCT00762190TakedaTAK-559

Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Start: Nov 2003Est. completion: Dec 2004348 patients
Phase 3Terminated
NCT00759720TakedaTAK-559 and glyburide

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

Start: Nov 2003Est. completion: Dec 2004447 patients
Phase 3Terminated
NCT00762112TakedaTAK-559

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Start: Nov 2003Est. completion: Dec 2004316 patients
Phase 3Terminated
NCT00225277TakedaPioglitazone

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

Start: Jul 2003Est. completion: Oct 2007547 patients
Phase 3Completed
NCT00138671PfizerSubcutaneous Insulin

A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD

Start: Jan 2003Est. completion: Sep 2008105 patients
Phase 3Terminated
NCT00136916PfizerInhaled Insulin

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

Start: Jun 2002Est. completion: Dec 2008635 patients
Phase 3Terminated
NCT00174993Eli Lilly and CompanyPioglitazone

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

Start: May 2001Est. completion: Jan 20054,373 patients
Phase 3Completed
NCT01010100BayerAcarbose

Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care

Start: Aug 2000Est. completion: May 2007204 patients
Phase 3Completed
NCT01208948Bausch + Lomb1,2 dithiolane 3 valeric acid

Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema

Start: Jul 2000Est. completion: Dec 2005520 patients
Phase 3Completed
NCT00521820TakedaPioglitazone

Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure

Start: Jun 2000Est. completion: Oct 2003518 patients
Phase 3Terminated
NCT02147041City TherapeuticsEGCG

The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides

Start: May 2012Est. completion: Aug 2014
Phase 2/3Unknown
NCT00562952RocheTelmisartan, Bisoprolol

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

Start: Nov 2007Est. completion: Dec 2011300 patients
Phase 2/3Completed
NCT05063734OxurionTHR-687 dose level 1

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Start: Aug 2021Est. completion: Jun 2022
Phase 2Terminated
NCT04527107OxurionTHR-149 dose level 1

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Start: Jul 2020Est. completion: Nov 2023
Phase 2Completed
NCT03499223OxurionRanibizumab 0.5mg

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

Start: Apr 2018Est. completion: Jul 2019
Phase 2Completed
NCT00457470PfizerAG-014699

A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)

Start: Jun 20070
Phase 2Withdrawn
NCT00425919PfizerPPM-204

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Start: Jan 2007Est. completion: Oct 2007500 patients
Phase 2Terminated
NCT00763347TakedaSYR-619

Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

Start: Nov 2006Est. completion: Feb 200782 patients
Phase 2Terminated

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
17h ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
3d ago

Obesity Health Care B2B Manager

Eli Lilly and Company
Czech Republic, Praha 8
4d ago

Genomic Medicine Unit (GMU) Drug Product Development 2026 Summer-Fall Co-op

Sanofi
Waltham, MA
4d ago
$27 - $60/hr

Global Medical Head, Obesity

AstraZeneca
Boston - MA, US
4d ago
$283K - $425K/yr

Senior Medical Science Liaison - Obesity- South TX

Amgen
Texas - Houston, US
5d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

31 late-stage (Phase 3) programs — potential near-term approvals
30 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)Gout(36)